Ethris Partners with Lonza to Develop Intranasal Spray-Dried mRNA Vaccines Against Respiratory Diseases
Shots:
- Ethris has entered into a collaboration agreement with Lonza to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates designed for mucosal delivery in pts with respiratory diseases
- As per the deal, Lonza will support Ethris’ vaccine candidates, which are based on Ethris’ stabilized non-immunogenic mRNA (SNIM RNA) & stabilized lipid nanoparticles (SNaP LNP) tech by providing spray-drying & particle engineering services at its Bend, US facility
- Collaboration will initially focus on developing a first-in-class intranasal mRNA vaccine candidate against influenza, with funding support from the Coalition for Epidemic Preparedness Innovations (CEPI)
Ref: Businesswire | Image: Ethris & Lonza
Related News:- Ethris Reports Topline Data from P-I trial of ETH47 for Uncontrollable Asthma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
